Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.

PORTON DOWN, England -

Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS).

Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK’s Veterinary Laboratories Agency

PORTON DOWN, England -

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory).

/C O R R E C T I O N — Enigma Diagnostics Limited/

PORTON DOWN, England - In the news release, “Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK’s Veterinary Laboratories Agency” issued on 30 Jun 2009 13:17 GMT, by Enigma Diagnostics Limited over PR Newswire, we are advised by a representative of the company that a second footnote has been added at the end of the fourth paragraph. The note references the following link: enigmadiagnostics.com/template2.php?page=news.php&m=4

Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office

PORTON DOWN, England - Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today it was issued European Patent EP1044283, which covers the use of endonuclease-based reporting in PCR and other nucleic acid amplification technologies. Becton, Dickinson and Company (BD) had filed a claim in opposition to this patent which was rejected by the European Patent Office at a proceeding in Munich on May 28.